The MRL Morning Show

Weekdays 6:00AM-9:00AM

AURORA, CO - DECEMBER 15: (EDITORIAL USE ONLY) Rocky Mountain Regional VA Medical Center investigational pharmacy technician Sara Berech holds a dose of the Johnson & Johnson COVID-19 vaccine before it is administered in a clinical trial on December 15, 2020 in Aurora, Colorado. The Johnson & Johnson vaccine could be submitted for emergency use by late January and is the only vaccine among leading candidates given as a single dose. (Photo by Michael Ciaglo/Getty Images)

European countries can continue to use the Johnson and Johnson COVID-19 vaccine. E.U. regulators say there are possible links to rare blood clot incidents, but said the benefits of the vaccine outweigh the risks.

The European Medicines Agency said a warning about using the vaccine with low blood platelets should be added. The agency said it researched all the cases of blood clotting, including one fatal case. More than seven-million Americans received the vaccine before it was paused here in the United States. There were eight reports of clotting, with six being series and of those, one death. Each EU member will have to decide if they will use the Johnson and Johnson vaccine.

Read the full article here.